State Of Wyoming Biomarin Pharmaceutical Inc Transaction History

State Of Wyoming

$676 Million
Q3 2024

A detailed history of State Of Wyoming transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, State Of Wyoming holds 719 shares of BMRN stock, worth $47,906. This represents 0.01% of its overall portfolio holdings.

Number of Shares

719

Previous 2,377 69.75%

Holding current value

$47,906

Previous $195,000 74.36%

% of portfolio

0.01%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $114,435 - $155,586	-1,658 Reduced 69.75%	719 $50,000
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $128,317 - $158,987	1,724 Added 264.01%	2,377 $195,000
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $26,735 - $31,581	319 Added 95.51%	653 $57,000
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $228 - $295	-3 Reduced 0.89%	334 $32,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $28,668 - $31,839	337 New	337 $29,000
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $32,291 - $43,343	399 New	399 $41,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $396,499 - $481,756	-5,547 Reduced 89.54%	648 $54,000
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $20,055 - $25,026	270 Added 4.56%	6,195 $478,000
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $27,540 - $35,124	384 Added 6.93%	5,925 $523,000
Q3 2021 Feb 11, 2022	SELL	$74.77 - $85.47 $81,349 - $92,991	-1,088 Reduced 16.41%	5,541 $428,000
Q2 2021 Feb 11, 2022	BUY	$75.51 - $84.79 $477,902 - $536,635	6,329 Added 2109.67%	6,629 $553,000
Q1 2021 Feb 08, 2022	BUY	$74.73 - $90.69 $22,419 - $27,207	300 New	300 $23,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account